Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2011-06-27

FDA Approved: SEREVENT DISKUS — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for SEREVENT DISKUS (salmeterol xinafoate) filed by GlaxoSmithKline LLC. This action updates the product’s labeling …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SEREVENT DISKUS (SALMETEROL XINAFOATE)

Snippet

SUPPL AP for SEREVENT DISKUS (SALMETEROL XINAFOATE)